September 16, 2026

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

Ref: Scrip Code: 543322

To,
The Manager - Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Name: ALIVUS

Dear Sirs,

Sub: Intimation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations")

In compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is hereby informed to you that the Company has incorporated a wholly owned subsidiary company "**Alivus Life Sciences Do Brasil Ltda.**" in the State of Sao Paulo, Brazil on September 15, 2026.

The relevant disclosure as prescribed under Regulation 30 of the SEBI LODR Regulations and SEBI circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed as Annexure 1.

Kindly take the above information on record.

Thanking you

Yours faithfully,
For Alivus Life Sciences Limited
(formerly Glenmark Life Sciences Limited)

RUDALF JOSEPH CORRIEA
Digitally signed by RUDALF JOSEPH CORRIEA
Date: 2026.09.16 12:54:18 +05'30'

Rudalf Corriea
Company Secretary & Compliance Officer
Encl.: As above

Annexure 1

S.No.	Particulars	Remarks
1.	Name of the target entity, details in brief such as size, turnover etc.	**Name:** Alivus Life Sciences Do Brasil Ltda. **Country of Incorporation:** Brazil **Authorized Capital:** R$ 500,000.00 (five hundred thousand reais), divided into 500,000 (five hundred thousand shares) **Turnover, Size:** Not Applicable since it is a newly incorporated company.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length"	This initial subscription does not fall within the purview of Related Party Transaction. The promoter / promoter group / group companies of the Company does not have any interest in Alivus Life Sciences Do Brasil Ltda.
3.	Industry to which the entity being acquired belongs	Pharmaceuticals
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Not applicable, as this is for incorporation of a wholly owned subsidiary
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Approved by Federative Republic of Brazil National Registrar of Legal Entities
6.	Indicative time period for completion of the acquisition	Not Applicable
7.	Nature of consideration - whether cash consideration or share swap and details of the same	Cash
8.	Cost of acquisition or the price at which the shares are acquired	The Company shall subscribe to the share capital of an amount not exceeding R$ 500,000.00 (five hundred thousand reais) (being 100% of the share capital).
9.	Percentage of shareholding / control acquired and / or number of shares acquired	100% of the paid up share capital will be held by the Company
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Date of Incorporation: September 15, 2026, 18:50 (Brazil Time) Turnover: Not Applicable since it is a newly incorporated company. Country: Brazil